Article Text

PDF
Randomised controlled trial
In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal
  1. Adrian G McNicholl,
  2. Javier P Gisbert
  1. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
  1. Correspondence to : Dr Javier P Gisbert, Gastroenterology Unit, Hospital de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), c/ Diego de León 62, Madrid 28006, Spain; Javier.p.gisbert{at}gmail.com

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMed.

Context

Helicobacter pylori infection is the main cause of several gastric diseases including gastritis, peptic ulcer and gastric cancer. Traditional anti-H. pylori treatments fail in up to 20–30% of naive patients requiring intervention. Failed attempts may cause the acquisition of resistance by H. pylori or the selection of resistant/resilient strains, hindering second-line treatments.

One of the most recommended second-line regimens is triple therapy with levofloxacin (LT); however, its efficacy has never been optimal, with an estimated pooled eradication rate of 79%.1 In order to improve these results, Liou and colleagues performed a randomised trial comparing LT with a levofloxacin containing sequential therapy (LS).

Methods

The study was …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.